Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
Ugo De GiorgiGiacomo CartenìDiana GiannarelliUmberto BassoLuca GalliEnrico CortesiClaudia CasertaSandro PignataRoberto SabbatiniAlessandra BearzSebastiano ButiGiovanni Lo ReAlfredo BerrutiSergio BracardaFrancesco CognettiFrancesca RastelliGiuseppe FornariniCamillo PortaDaniele TurciCora N SternbergGiuseppe Procopionull nullPublished in: BJU international (2018)
The safety and efficacy observed were consistent with those reported in the pivotal Checkmate 025 trial. Results in patients with non-clear-cell mRCC who were elderly, pretreated with everolimus, and had bone and/or brain metastases encourage the use of nivolumab in these categories of patients.